News Release

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: May 4, 2026

Peer-Reviewed Publication

Society of Nuclear Medicine and Molecular Imaging

Reston, VA (May 4, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

Summaries of the newly published research articles are provided below.

Wearable Brain PET Enables Real-Time Imaging Beyond the Lab
A new wearable brain imaging system, SmartBrain, captures brain activity without requiring patients to remain still. Using advanced detectors, it produced high-resolution images in lab tests, models, animal studies, and an initial human scan, demonstrating strong performance across key imaging benchmarks.

Dual-Tracer PET Scans Help Predict Survival in Liver Cancer
Researchers tested two imaging tracers before and after one month of sorafenib therapy in advanced liver cancer patients. By measuring tumor metabolism and size, they identified imaging markers—especially from standard glucose-based scans—that were strongly linked to one-year survival outcomes.

New PET Tracer Tracks Prostate Cancer Spread with Precision
Scientists evaluated a novel PET imaging tracer targeting prostatic acid phosphatase in patients with advanced prostate cancer. The tracer showed rising uptake in tumors over time, clear contrast against healthy tissue, predictable body distribution, and a relatively low radiation dose in early human imaging tests.

Kidney Function Impact of Targeted Prostate Cancer Therapy Assessed
A large registry study examined kidney function in prostate cancer patients receiving 177Lu-PSMA-617. Tracking changes over two years, researchers found a small, gradual decline in kidney performance, with higher cumulative treatment doses linked to slightly faster reductions.

Visit the JNM website for the latest research and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.